Medtronic Receives FDA Approval for New Arm Indication for Guardian(TM) Sensor 3 - Further Enhancing the MiniMed(TM) 670G Hybrid Closed Loop Experience

February 26, 2018

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved a new arm indication for the Guardian(TM) Sensor 3. This expanded indication will enable patients to wear the sensor on the upper arm - delivering more flexibility and enhanced performance for users, as well as improved accuracy, with a MARD of 8.7 percent following typical calibration methods used with the MiniMed(TM) 670G system. The Guardian Sensor 3 is Medtronic's newest and most accurate CGM to-date and is the only sensor FDA approved to control automated insulin delivery via a hybrid closed loop system - the MiniMed 670G system.

Read more >

Medtronic Introduces MiniMed(TM) Mio(TM) Advance Infusion Set for People with Diabetes

February 21, 2018

Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, today introduced the MiniMed(TM) Mio(TM) Advance infusion set. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives patients a simpler, faster and more convenient set change with fewer steps1,2. The new infusion set will first be available in select countries around the world with plans to expand availability over time.

Read more >

Medtronic Announces Upcoming Data Presentations at the Advanced Technologies and Treatments for Diabetes 11th International Conference

February 13, 2018

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria, from February 14-17. A significant portion of the scientific data being presented focuses on the company's insulin pump systems, including new data on the benefits of the latest SmartGuard(TM) technology that drives the MiniMed(TM) 670G system1 in children with type 1 diabetes. Medtronic will also host an exclusive symposium titled "Using Technology to Increase Time in Range: The New Goal for Glycemic Control" on Thursday, February 15, from 10:30-12:00 CET.

Read more >

Medtronic Announces First Economic Analysis Demonstrating Benefits of Professional CGM in People with Type 2 Diabetes

October 25, 2017

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced data from the first economic analysis conducted on the use of professional continuous glucose monitoring (CGM) in people with type 2 diabetes. Data from the study demonstrated significant cost avoidance to the healthcare system when used during a therapy change or when used at least twice per year. The results also reinforced the well-established clinical benefits of professional CGM use in people with type 2 diabetes. The study, published in the Journal of Medical Economics, retrospectively analyzed real-world data of over 5,600 people who used professional CGM in the United States using health insurance medical and pharmacy claims, enrollment data and laboratory data.

Read more >

Medtronic Announces Voluntary Recall of Diabetes Infusion Sets

September 11, 2017

Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps or glucose sensors.

Read more >

View all Announcements >

Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Janet Kim
Director, Communications

Pamela Reese
Director, Communications

For all other media inquiries please select the appropriate Global Public and Media Relations contact

Media Kits